Company Encyclopedia
View More
name
Ridgetech
RDGT.US
Ridgetech, Inc. operates as a wholesale distributor of pharmaceutical and other healthcare products in the People’s Republic of China. It operates through three segments: Retail Drugstores, Online Pharmacy, and Drug Wholesale. The company engages in offline and online wholesale distribution of pharmaceutical products, including prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicines (TCM), personal and family care products, and medical devices, as well as convenience products comprising consumable, seasonal, and promotional items.
76.69 M
RDGT.USMarket value -Rank by Market Cap -/-

Financial Score

11/11/2025 Update
C
Drug RetailIndustry
Industry Ranking2/4
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-6.45%D
    • Profit Margin8.50%B
    • Gross Margin3.20%E
  • Growth ScoreC
    • Revenue YoY-3.24%D
    • Net Profit YoY340.76%A
    • Total Assets YoY-32.16%E
    • Net Assets YoY107.35%A
  • Cash ScoreC
    • Cash Flow Margin1176.83%B
    • OCF YoY-3.24%D
  • Operating ScoreA
    • Turnover1.5A
  • Debt ScoreC
    • Gearing Ratio54.04%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Ridgetech Inc. Reports FY 2025 Revenue Decline of 3.2% to $119.97M, Net Income of $10.20M, EPS at $1.84

    Ridgetech Inc. reported a 3.2% decline in FY 2025 revenue to $119.97 million, with a net income of $10.20 million and EPS of $1.84. The revenue drop was mainly due to a 4.3% decrease in offline wholesale activities. Despite the decline, the company improved from a net loss of $4.23 million last year. Cash and cash equivalents rose significantly to $12.78 million. Ridgetech's strategic transformation included the acquisition of Ridgeline, contributing to its online and offline distribution channels, and it aims for long-term sustainable growth.

    Reuters·
    US
    RDGT
    +27.14%
    Reuters·
    US
    RDGT
    +27.14%

    Ridgetech, Inc. Reports Fiscal Year 2025 Financial Results | RDGT Stock News

    Ridgetech, Inc. (Nasdaq: RDGT) reported its fiscal year 2025 financial results, showing stable revenue of approximately $120 million despite significant changes, including the divestment of its retail pharmacy business and the acquisition of Ridgeline and Allright. The company experienced a 3.2% revenue decrease from the previous year, with a net income of $10.20 million compared to a net loss last year. The gross profit was $3.84 million, reflecting a gross margin of 3.2%. Ridgetech is focusing on expanding its online and offline wholesale distribution in China's healthcare sector.

    StockTitan·
    US
    RDGT
    +27.14%
    StockTitan·
    US
    RDGT
    +27.14%

    Ridgetech Completes Capital Restructuring with Share Subdivision

    Ridgetech, Inc. has completed a capital restructuring involving a reduction in par value from US$0.24 to US$0.001 per share and a subdivision of authorized shares into 240 new shares. This restructuring, approved on February 25, 2025, aims to enhance financial flexibility and market positioning, resulting in an authorized share capital of US$36,010,000. However, RDGT stock is rated as Underperform by TipRanks’ AI Analyst due to financial challenges and bearish technical indicators.

    Tip Ranks·
    US
    RDGT
    +27.14%
    Tip Ranks·
    US
    RDGT
    +27.14%

    Ridgetech, Inc. Completes Strategic Acquisition and Divestiture, Rebrands from China Jo-Jo Drugstores

    Ridgetech, Inc., formerly China Jo-Jo Drugstores, has completed a strategic acquisition of Ridgeline International Limited and a divestiture of equity in Zhejiang Jiuxin Investment Management Co. Ltd. to Oakview International Limited. These changes were approved by shareholders on February 25, 2025, and finalized on February 28, 2025, marking a significant rebranding and restructuring for the company, which operates in the pharmaceutical sector. The current market cap is $9.95M, with a year-to-date price performance of -12.02%.

    Tip Ranks·
    US
    CJJD
    0.00%
    US
    RDGT
    +27.14%
    Tip Ranks·
    US
    CJJD
    0.00%
    US
    RDGT
    +27.14%

    China Jo-Jo Drugstores Announces Strategic Business Restructuring to Strengthen Wholesale Business for Greater Profitability and Growth | CJJD Stock News

    China Jo-Jo Drugstores, Inc. (Nasdaq:CJJD) has announced a strategic restructuring to focus on its wholesale business, enhancing profitability. This includes acquiring Allright (Hangzhou) Internet Technology Co. Ltd. and divesting its retail business to current CEO Lei Liu and director Li Qi. The transactions are expected to close in Q1 2025, pending shareholder approval. Frank Zhao will serve as interim CEO post-restructuring. The company aims to improve operational efficiency and create long-term value for shareholders through this transition.

    StockTitan·
    US
    CJJD
    0.00%
    US
    RDGT
    +27.14%
    StockTitan·
    US
    CJJD
    0.00%
    US
    RDGT
    +27.14%